Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 18 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 70				Other				MM-ADJ-5 NCT00226408


2.		PegIntron vs IntronA in CMAJCC Stage II (EADO 2001/CMII Trial).

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 75				Other				9267-01 2001-034, NCT00221702


3.		GEM05 for Patients With Multiple Myeloma Under 65 Years

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				65 and under				Other				2005-001110-41 NCT00461747

Last Modified: 9/18/2008 First Published: 12/4/2007


4.		Phase III Randomized Study of Depot Octreotide Acetate and Interferon alfa-2b Versus Depot Octreotide Acetate and Bevacizumab in Patients With Unresectable Metastatic or Locally Advanced, High-Risk Neuroendocrine Carcinoid Tumor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Not specified				NCI				SWOG-S0518 S0518, NCT00569127


5.		Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				2006-0354 NCT00629200


6.		Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				A6181065 NCT00267748

First Published: 5/4/2007


7.		Phase II Study of Neoadjuvant Oxaliplatin, Doxorubicin Hydrochloride, Fluorouracil, and Recombinant Interferon Alfa-2b in Patients With Unresectable, Nonmetastatic Hepatocellular Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				16 to 75				Other, Pharmaceutical / Industry				SINGAPORE-OC-GI-01-06 OC-GI-01-06, SINGAPORE-IRB-06-16-HEP, SINGAPORE-CTC0600327, SPRI-SINGAPORE-OC-GI-01-06, NCT00471484


8.		Immunotherapy for AML, ALL, BP CML, and MDS Relapsed After Allogeneic Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 1				Other				2219 NCT00548847


9.		Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				2006-0962 NCT00561912


10.		Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				MEL11 NCT00613509

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute